<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920302-0013</DOCNO><DOCID>920302-0013.</DOCID><HL>   Scherer `Comfortable'   With Profit Estimtes   For Its Fiscal Year</HL><DATE>03/02/92</DATE><SO>WALL STREET JOURNAL (J), PAGE A7D</SO><CO>   SHR</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DOW JONES INTERVIEW (CEO)MEDICAL SUPPLIES, EYEGLASS MANUFACTURERS (MDS)</IN><NS>EXCLUSIVE INTERVIEW WITH CHIEF EXECUTIVES (CEO)EARNINGS PROJECTIONS (ERP)</NS><RE>MICHIGAN (MI)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   TROY, Mich. -- R.P. Scherer Corp. said it's &quot;comfortable&quot;with analysts' estimates that the company will earn, beforecharges, between 90 cents and 95 cents a share in its fiscalyear ending March 31.   That would compare with the 64 cents a share thesoft-gelatin capsule maker earned a year ago before chargestaken associated with going public in October 1991.</LP><TEXT>   Scherer went private in 1989 in a $352 million leveragedbuy-out led by management. Proceeds from the public offeringwere used toward retiring about half of the debt used for thebuy-out.   After taking charges related to the early retirement ofdebt and other costs associated with the buy-out, the companyposted a loss last year of $6.7 million, or $6.10 a share, onsales of $299 million. R.P. Scherer officials declined toforecast annual or fourth-quarter earnings.   Company officials said they expect to take a &quot;smallcharge&quot; in this fourth quarter ending March 31 related to anew stock option plan.   Still, &quot;this has been the most successful year the companyhas had,&quot; said Aleksander Erdeljan, R.P. Scherer's president.&quot;Even withstanding the difficult economy, we remain buoyantand strong. We expect much of the same next year.&quot;   R.P. Scherer's core business is developing soft-gelatinproducts used by pharmaceutical, cosmetic, vitamin andnutrition industries. It dominates the soft-gelatin capsuleindustry with nearly 70% of the market, financial analystssaid.   R.P. Scherer is particularly upbeat about prospects fortwo new drug delivery systems -- rapidly dissolving Zydis andPulsincap, which is designed to release a drug at apredetermined time or site in the gastrointestinal tract.</TEXT></DOC>